Literature DB >> 21418164

CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).

K L Heading1, L K Brockley, P F Bennett.   

Abstract

OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity. CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively. The incidence of hepatic failure was 1.2%.
CONCLUSIONS: CCNU-associated toxicity in dogs is common, but is usually not life threatening.
© 2011 The Authors. Australian Veterinary Journal © 2011 Australian Veterinary Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418164     DOI: 10.1111/j.1751-0813.2011.00690.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  8 in total

Review 1.  Oncolytic virotherapy of canine and feline cancer.

Authors:  Ivaylo Gentschev; Sandeep S Patil; Ivan Petrov; Joseph Cappello; Marion Adelfinger; Aladar A Szalay
Journal:  Viruses       Date:  2014-05-16       Impact factor: 5.048

Review 2.  Systematic Review of Brain Tumor Treatment in Dogs.

Authors:  H Hu; A Barker; T Harcourt-Brown; N Jeffery
Journal:  J Vet Intern Med       Date:  2015-09-16       Impact factor: 3.333

3.  Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.

Authors:  J H Burton; S D Stanley; H K Knych; C O Rodriguez; K A Skorupski; R B Rebhun
Journal:  J Vet Intern Med       Date:  2015-12-18       Impact factor: 3.333

Review 4.  Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic.

Authors:  Aurore Laprais; Thierry Olivry
Journal:  BMC Vet Res       Date:  2017-02-21       Impact factor: 2.741

5.  ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs.

Authors:  Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

6.  Effect of dilution of canine blood samples on the specificity of saline agglutination tests for immune-mediated hemolysis.

Authors:  Prudence L Sun; Unity Jeffery
Journal:  J Vet Intern Med       Date:  2020-11-10       Impact factor: 3.333

7.  Prediction of cancer drugs by chemical-chemical interactions.

Authors:  Jing Lu; Guohua Huang; Hai-Peng Li; Kai-Yan Feng; Lei Chen; Ming-Yue Zheng; Yu-Dong Cai
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

8.  Phase I dose-escalation study of nimustine in tumor-bearing dogs.

Authors:  Masashi Takahashi; Yuko Goto-Koshino; Kenjiro Fukushima; Hideyuki Kanemoto; Ko Nakashima; Yasuhito Fujino; Koichi Ohno; Yasuyuki Endo; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2014-02-10       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.